1. Home
  2. SYNX vs PPBT Comparison

SYNX vs PPBT Comparison

Compare SYNX & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silynxcom Ltd.

SYNX

Silynxcom Ltd.

N/A

Current Price

$1.23

Market Cap

7.1M

Sector

N/A

ML Signal

N/A

Logo Purple Biotech Ltd.

PPBT

Purple Biotech Ltd.

N/A

Current Price

$3.84

Market Cap

45.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SYNX
PPBT
Founded
2005
2010
Country
Israel
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
45.3M
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
SYNX
PPBT
Price
$1.23
$3.84
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.3M
70.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$32.35
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$0.41
52 Week High
$4.55
$5.18

Technical Indicators

Market Signals
Indicator
SYNX
PPBT
Relative Strength Index (RSI) 55.93 70.54
Support Level $0.90 $0.57
Resistance Level $1.31 $5.18
Average True Range (ATR) 0.17 0.32
MACD 0.02 0.18
Stochastic Oscillator 31.25 72.33

Price Performance

Historical Comparison
SYNX
PPBT

About SYNX Silynxcom Ltd.

Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Share on Social Networks: